CBT Stock Analysis: Cabot | NYSE

Specialty Chemicals | NYSE, USA | Market Cap: 4.522m USD | 12M Return: 8.3% | Charts, Fundamentals & Technical Analysis

Reinforcing Carbons, Specialty Carbons, Fumed Silica, Fumed Alumina
Total Rating 62
Safety 79
Buy Signal -0.42
Specialty Chemicals
Industry Rotation: -1.8
Market Cap: 4.52B
Avg Turnover: 52.7M
Risk 3d forecast
Volatility43.6%
VaR 5th Pctl7.15%
VaR vs Median-0.41%
Reward TTM
Sharpe Ratio0.28
Rel. Str. IBD55.1
Rel. Str. Peer Group85.3
Character TTM
Beta0.812
Beta Downside0.987
Hurst Exponent0.477
Drawdowns 3y
Max DD48.78%
CAGR/Max DD0.17
CAGR/Mean DD0.45
EPS (Earnings per Share) EPS (Earnings per Share) of CBT over the last years for every Quarter: "2021-06": 1.35, "2021-09": 1.11, "2021-12": 1.29, "2022-03": 1.69, "2022-06": 1.73, "2022-09": 1.55, "2022-12": 0.98, "2023-03": 1.33, "2023-06": 1.42, "2023-09": 1.65, "2023-12": 1.56, "2024-03": 1.78, "2024-06": 1.92, "2024-09": 1.8, "2024-12": 1.76, "2025-03": 1.9, "2025-06": 1.9, "2025-09": 1.7, "2025-12": 1.53, "2026-03": 1.61,
EPS CAGR: 10.89%
EPS Trend: 78.2%
Last SUE: 1.82
Qual. Beats: 2
Revenue Revenue of CBT over the last years for every Quarter: 2021-06: 917, 2021-09: 904, 2021-12: 968, 2022-03: 1092, 2022-06: 1149, 2022-09: 1112, 2022-12: 965, 2023-03: 1033, 2023-06: 968, 2023-09: 965, 2023-12: 958, 2024-03: 1019, 2024-06: 1016, 2024-09: 1001, 2024-12: 955, 2025-03: 936, 2025-06: 923, 2025-09: 899, 2025-12: 849, 2026-03: 904,
Rev. CAGR: -3.80%
Rev. Trend: -84.1%
Last SUE: -0.31
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Seasonality 10.5 years of data

Jan +1.6% 0
Feb +5.1% 31
Mar -2.7% 15
Apr -0.9% 27
May +7.5% 17
Jun +0.7% 14
Jul -0.3% 5
Aug -1.5% 22
Sep -3.2% 43
Oct -1.1% 8
Nov +1.4% 6
Dec +0.2% 8

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CBT Cabot

Cabot Corporation is a U.S.-based specialty chemicals and performance materials company operating through two segments: Reinforcement Materials and Performance Chemicals. Its Reinforcement Materials business centers on carbon black, a petroleum-derived feedstock that serves as the primary reinforcing filler in rubber compounds, with the global tire industry as its dominant end-market. The Performance Chemicals segment supplies higher-value specialty carbons, fumed silica, fumed alumina, aerogels, masterbatches, conductive compounds, inkjet colorants, and carbon nanotubes to industrial customers.

Cabots products are used across tires, industrial rubber goods, lithium-ion and lead-acid batteries for electric vehicles, inks, coatings, adhesives, cosmetics, and pharmaceuticals. Distribution is handled globally through sales representatives and distributors spanning the Americas, Europe, the Middle East, Africa, and Asia Pacific. Founded in 1882 and headquartered in Boston, Massachusetts, the company is listed on the NYSE under the ticker CBT and is classified within the Materials sector, specifically the Commodity Chemicals sub-industry.

Headlines to Watch Out For
  • Tire reinforcement demand tracks global auto and replacement tire cycles
  • EV battery adoption lifts conductive additives volume and pricing
  • Energy and feedstock costs pressure specialty chemicals margins
Piotroski VR-10 (Strict) 8.0
Net Income: 285.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.17 > 1.0
NWC/Revenue: 13.40% < 20% (prev 20.09%; Δ -6.69% < -1%)
CFO/TA 0.17 > 3% & CFO 671.0m > Net Income 285.0m
Net Debt (1.13b) to EBITDA (755.0m): 1.50 < 3
Current Ratio: 1.45 > 1.5 & < 3
Outstanding Shares: last quarter (52.2m) vs 12m ago -4.04% < -2%
Gross Margin: 24.95% > 18% (prev 24.87%; Δ 0.08% > 0.5%)
Asset Turnover: 93.09% > 50% (prev 103.3%; Δ -10.19% > 0%)
Interest Coverage Ratio: 7.71 > 6 (EBIT TTM 586.0m / Interest Expense TTM 76.0m)
Altman Z'' 4.11
A: 0.12 (Total Current Assets 1.55b - Total Current Liabilities 1.07b) / Total Assets 3.90b
B: 0.47 (Retained Earnings 1.83b / Total Assets 3.90b)
C: 0.15 (EBIT TTM 586.0m / Avg Total Assets 3.84b)
D: 0.71 (Book Value of Equity 1.57b / Total Liabilities 2.21b)
Altman-Z'' = 4.11 = AA
Beneish M -3.12
DSRI: 0.97 (Receivables 657.0m/739.0m, Revenue 3.58b/3.91b)
GMI: 1.00 (GM 24.87% / 24.95%)
AQI: 1.01 (AQ_t 0.15 / AQ_t-1 0.15)
SGI: 0.91 (Revenue 3.58b / 3.91b)
TATA: -0.10 (NI 285.0m - CFO 671.0m) / TA 3.90b)
Beneish M = -3.12 (Cap -4..+1) = AA
What is the price of CBT shares?

As of July 09, 2026, the stock is trading at USD 82.90 with a total of 985,911 shares traded. Over the past week, the price has changed by -8.72%, over one month by -0.02%, over three months by +9.17% and over the past year by +8.33%.

Current recommended Stop Loss: 79.30 (which is 4.3% or 1.3 ATR below the current price).

Is CBT a buy, sell or hold?

Cabot has received a consensus analysts rating of 3.60. Therefore, it is recommended to hold CBT.

  • StrongBuy: 2
  • Buy: 0
  • Hold: 2
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the CBT price?
Analysts Target Price 88.5 6.8%
Cabot (CBT) - Fundamental Data Overview as of 08 July 2026
Market Cap USD = 4.52b (4.52b USD * 1.0 USD.USD)
P/E Trailing = 16.5283
P/E Forward = 10.6157
P/S = 1.2649
P/B = 2.8428
P/EG = 1.0017
Revenue TTM = 3.58b USD
EBIT TTM = 586.0m USD
EBITDA TTM = 755.0m USD
Long Term Debt = 863.0m USD (from longTermDebt, last quarter)
Short Term Debt = 436.0m USD (from shortTermDebt, last quarter)
Debt = 1.38b USD (from shortLongTermDebtTotal, last quarter) + Leases 85.0m
Net Debt = 1.13b USD (calculated: Debt 1.38b - CCE 252.0m)
Enterprise Value = 5.65b USD (4.52b + Debt 1.38b - CCE 252.0m)
Interest Coverage Ratio = 7.71 (Ebit TTM 586.0m / Interest Expense TTM 76.0m)
EV/FCF = 12.32x (Enterprise Value 5.65b / FCF TTM 459.0m)
FCF Yield = 8.12% (FCF TTM 459.0m / Enterprise Value 5.65b)
FCF Margin = 12.84% (FCF TTM 459.0m / Revenue TTM 3.58b)
Net Margin = 7.97% (Net Income TTM 285.0m / Revenue TTM 3.58b)
Gross Margin = 24.95% ((Revenue TTM 3.58b - Cost of Revenue TTM 2.68b) / Revenue TTM)
Gross Margin QoQ = 24.00% (prev 24.85%)
Tobins Q-Ratio = 1.45 (Enterprise Value 5.65b / Total Assets 3.90b)
Interest Expense / Debt = 5.49% (Interest Expense 76.0m / Debt 1.38b)
Taxrate = 36.38% (187.0m / 514.0m)
NOPAT = 372.8m (EBIT 586.0m * (1 - 36.38%))
Current Ratio = 1.45 (Total Current Assets 1.55b / Total Current Liabilities 1.07b)
Debt / Equity = 0.88 (Debt 1.38b / totalStockholderEquity, last quarter 1.57b)
Debt / EBITDA = 1.50 (Net Debt 1.13b / EBITDA 755.0m)
Debt / FCF = 2.47 (Net Debt 1.13b / FCF TTM 459.0m)
Total Stockholder Equity = 1.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.42% (Net Income 285.0m / Total Assets 3.90b)
RoE = 18.29% (Net Income TTM 285.0m / Total Stockholder Equity 1.56b)
RoCE = 24.20% (EBIT 586.0m / Capital Employed (Equity 1.56b + L.T.Debt 863.0m))
RoIC = 12.08% (NOPAT 372.8m / Invested Capital 3.09b)
WACC = 7.59% (E(4.52b)/V(5.91b) * Re(8.84%) + D(1.38b)/V(5.91b) * Rd(5.49%) * (1-Tc(0.36)))
Discount Rate = 8.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.88 | Cagr: -2.92%
[DCF] Terminal Value 77.97% ; FCFF base≈390.6m ; Y1≈447.8m ; Y5≈659.0m
[DCF] Fair Price = 170.2 (EV 9.92b - Net Debt 1.13b = Equity 8.78b / Shares 51.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 78.18 | EPS CAGR: 10.89% | SUE: 1.82 | # QB: 2
Revenue Correlation: -84.15 | Revenue CAGR: -3.80% | SUE: -0.31 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.65 | Chg30d=+2.19% | Revisions=-17% | Analysts=6
EPS current Year (2026-09-30): EPS=6.32 | Chg30d=+0.91% | Revisions=+17% | GrowthEPS=-12.9% | GrowthRev=-3.0%
EPS next Year (2027-09-30): EPS=7.00 | Chg30d=+1.01% | Revisions=+50% | GrowthEPS=+10.8% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: +25% (up=6, down=3)